Vibin™ is a truth-driven news and community platform built to reconnect humanity through real stories, unbiased news, art, and healing. No noise. Just connection.

Investing.com-- India’s Sun Pharmaceutical Industries (NSE:SUN) and Lupin Ltd (NSE:LUPN) are seeking regulatory approval to develop affordable anti-obesity pills as the country faces a mounting obesity crisis, Mint reported on Monday, citing documents and a person familiar with the matter. The Drugs Controller General of India (DCGI) has cleared Sun Pharma to conduct a large-scale Phase III trial for its semaglutide tablets, while Lupin has received approval to begin a bioequivalence study to show its generic version performs similarly to the original, Mint said. Currently, anti-obesity drugs such as Novo Nordisk’s (CSE:NOVOb) Wegovy and Eli Lilly’s (NYSE:LLY) Mounjaro remain costly and largely limited to injections, reducing accessibility for Indian patients. A Lancet study has projected India could have 450 million overweight and obese adults by 2050. Experts cited by Mint said generics could bring costs down but warned against misuse, stressing the need for strict medical supervision and regulatory safeguards. With LLY making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed LLY alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including LLY, could offer substantial returns as the market corrects. In 2025 alone, our AI identified several undervalued stocks that later surged by 50% or more. Is LLY poised for similar growth? Don't miss the opportunity to find out.

All the science news you can handle in a single feed

Being human means being conflicted — and today I’m tackling two issues that have me torn. First: SNAP benefits may soon exclude snack foods, sodas, and chips. On one hand, we face an obesity crisis and need healthier choices. On the other, should poor people be policed on what they can eat while the wealthy buy whatever they want? Second: Algorithms are shaping how we see race. Why do viral videos often show Black people “acting out,” while similar (or worse) white content isn’t pushed as widely? Is the algorithm racist — and reinforcing dangerous stereotypes? Being a liberal, being human, means wrestling with contradictions. I’ll share my thoughts, where I’m conflicted, and what I’m absolutely clear on. ✨ Support The Karel Cast at patreon.com/reallykarel 📺 Watch, like, and subscribe at youtube.com/reallykarel 🎧 Listen on Apple, Spotify, iHeart, Spreaker, and everywhere podcasts stream. #KarelCast, #LiberalPodcast, #ProgressiveTalk, #SNAPBenefits, #FoodStamps, #ObesityCrisis, #FoodJustice, #PoorPeoplesRights, #VeganLife, #SocialJustice, #RacialBias, #AlgorithmRacism, #BlackVoicesMatter, #MediaBias, #EqualityForAll, #HumanStruggles, #ProgressivePolitics, #LasVegasPodcast, #PodcastCommunity, #IndependentMedia https://youtube.com/live/q_kYeFYavYY

YouTube video by 5 Whole Minutes

Scholarly and community articles about food and food systems

Novo Nordisk’s shares fell by more than 20% on Tuesday

YouTube video by HealthDay

'Eat less, move more' is failing.

Obesity is implicated in a dramatic rise in digestive diseases and cancers across Europe, especially among those under 50. Urgent action is needed.

Chamber is a specialist publisher of UK policy and politics. Along with our Parliamentary Journal we publish policy papers, books and reports. Discover the

Social justice, Digital Equity, Poverty, Accessible Technology, Marginalized communities, Pacific, COFA, Veterans, Low-Income, Affordable housing

A complex systems study reveals how city size, services, and structure can reshape the link between ADHD and obesity, offering fresh insight into public health and urban policy.

Drugs that both activate and block the GIP receptor reduce weight through different brain mechanisms, offering a new direction for targeted obesity treatments. Drugs that target the receptors for the...

A study by Pennington Biomedical Research Center reveals a 210% increase in U.S. adults with BMI over 60 kg/m² since 2001, highlighting the urgent need for targeted healthcare strategies.

But what if there's more to it than that?